Department of Internal Medicine and Clinical Pharmacology, Medical University of Silesia, Katowice, Poland.
Department of Pediatrics in Bytom, School of Health Sciences in Katowice, Medical University of Silesia, Katowice, Poland.
J Clin Pharmacol. 2022 Dec;62(12):1566-1573. doi: 10.1002/jcph.2123. Epub 2022 Jul 30.
Both metformin and statins reduce thyroid antibody titers in individuals with Hashimoto thyroiditis. The present study compared the impact of low-grade systemic inflammation and insulin resistance on levothyroxine action in subjects with this disorder. The study included 3 groups of women with autoimmune subclinical hypothyroidism matched for thyroid antibody titers and hormone levels: patients receiving atorvastatin (group A) or metformin (group B) and statin- and metformin-naïve women (group C). Over the entire study period (6 months), all individuals received levothyroxine. Titers of thyroid antibodies, as well as concentrations of thyrotropin, free thyroid hormones, prolactin, lipids, glucose, insulin, high-sensitivity C-reactive protein (hsCRP), and 25-hydroxyvitamin D were assessed at baseline and 6 months later. At baseline, the study groups differed in plasma lipids, insulin sensitivity, and hsCRP. In all groups of patients, levothyroxine decreased thyroid antibody titers, reduced thyrotropin levels and increased free thyroid hormone levels. Treatment-induced changes in antibody titers and free thyroid hormone levels were strongest in group A, while the changes in thyrotropin were most pronounced in group B. The decrease in antibody titers correlated to a greater degree with hsCRP levels than with insulin sensitivity. The obtained results suggest that low-grade systemic inflammation is a more important factor determining the impact of levothyroxine on thyroid autoimmunity and thyroid hormone levels than insulin resistance.
二甲双胍和他汀类药物均可降低桥本甲状腺炎患者的甲状腺抗体滴度。本研究比较了低水平全身炎症和胰岛素抵抗对该疾病患者左甲状腺素作用的影响。该研究纳入了三组甲状腺抗体滴度和激素水平匹配的自身免疫亚临床甲状腺功能减退症女性患者:接受阿托伐他汀(A 组)或二甲双胍(B 组)治疗的患者和他汀类药物及二甲双胍均未使用的女性(C 组)。在整个研究期间(6 个月),所有患者均接受左甲状腺素治疗。在基线和 6 个月时评估甲状腺抗体滴度以及促甲状腺激素、游离甲状腺激素、催乳素、脂质、葡萄糖、胰岛素、高敏 C 反应蛋白(hsCRP)和 25-羟维生素 D 的浓度。基线时,研究组在血浆脂质、胰岛素敏感性和 hsCRP 方面存在差异。在所有患者组中,左甲状腺素均降低了甲状腺抗体滴度,降低了促甲状腺激素水平并增加了游离甲状腺激素水平。在 A 组中,抗体滴度和游离甲状腺激素水平的治疗诱导变化最强,而在 B 组中,促甲状腺激素的变化最为明显。抗体滴度的降低与 hsCRP 水平的相关性大于与胰岛素敏感性的相关性。研究结果表明,与胰岛素抵抗相比,低水平全身炎症是决定左甲状腺素对甲状腺自身免疫和甲状腺激素水平影响的更重要因素。